Conference focused on elevating clinical practice and research to improve patient outcomes

Miami (July 7, 2026) – The Bronchiectasis and NTM Association announced today that research leveraging data from the Bronchiectasis and NTM Research Registry was featured in four abstracts presented at the World Bronchiectasis Conference, held June 24-27, 2026, in Hannover, Germany.

The abstracts are:

• “The Impact of Proton Pump Inhibitor (PPI) Use on Exacerbation Rates in Patients with Bronchiectasis: An Analysis of the US Bronchiectasis and NTM Research Registry,” which examined the impact proton pump inhibitor use has on future exacerbations and a person’s airway microbiome.
• “Characterizing CFTR-Related Disorder Bronchiectasis and Response to Modulator Therapy: A Prospective Multicenter Registry Cohort,” which evaluated clinical outcomes of people with clinically diagnosed or suspected cystic fibrosis transmembrane conductance regulator (CFTR)-related bronchiectasis who were prescribed modulator therapy.
• “Association of Inhaled Corticosteroid Use and Clinical Outcomes in Patients with Bronchiectasis,” which analyzed clinical outcomes for people with bronchiectasis who were prescribed inhaled corticosteroids.
• “Comparison of Aerobika versus other PEP therapies, in addition to inhaled hypertonic saline, among adult patients in the U.S. Bronchiectasis and Nontuberculous Mycobacteria (NTM) Research Registry,” which studied clinical outcomes for people with bronchiectasis who were using Aerobika® and hypertonic saline compared to those using other positive expiratory pressure (PEP) devices and hypertonic saline.

The Registry, an initiative of the Bronchiectasis and NTM Association, is a national database that collects clinical data from individuals diagnosed with non-cystic fibrosis (non-CF) bronchiectasis and nontuberculous mycobacterial (NTM) pulmonary disease. It includes participants from multiple clinical institutions across the United States to help support collaborative research and planning of multi-center clinical trials.

The Bronchiectasis and NTM Association would like to acknowledge that the Registry is supported in part by corporate donors, all of which can be found on the Supporters page of the Association website.

For more information about the Bronchiectasis and NTM Research Registry, visit www.bronchandntm.org.

###

About Bronchiectasis and NTM Lung Disease

Bronchiectasis is a chronic lung disease characterized by enlarged airways that are thickened and/or scarred. These permanently widened airways lead to a buildup of mucus and impaired clearance of bacteria from the lungs. Between 340,000 and 522,000 adults are receiving treatment in the U.S.

Nontuberculous mycobacterial (NTM) pulmonary disease is a chronic respiratory condition caused by certain types of mycobacteria commonly found in the environment, such as in soil and water. NTM pulmonary disease predominantly affects individuals with compromised immune systems or pre-existing lung conditions, such as bronchiectasis and chronic obstructive pulmonary disease (COPD). NTM lung disease affects tens of thousands of individuals in the U.S. with rates of infection on the rise.

About the Bronchiectasis and NTM Association

The Bronchiectasis and NTM Association’s mission is to improve the lives of people with bronchiectasis, nontuberculous mycobacterial lung (NTM) disease, or both conditions. The Association accomplishes this by providing education, supporting advocacy, furthering research, and advancing high-quality, specialized care. For more information, visit www.bronchandntm.org.

Contact:                           
Brittany Irish
805-465-2497
brittany@bronchandntm.org